Postmarketing Outcomes of CD19-Directed CAR T-Cell Agent Axicabtagene Ciloleucel for Treatment of Large B-Cell Lymphoma in the United States

December 7-10, 2019; Orlando, Florida
Despite axi-cel being used in older patients and in more patients with high-risk disease, real-world efficacy and safety data for axi-cel in patients with large B-cell lymphoma was comparable to findings from the registrational ZUMA-1 trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 197 KB
Released: December 16, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

CCO printable treatment algorithm and toxicity management table to help optimize care of your patients with follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Released: September 30, 2020

Jacob D. Soumerai, MD, on how managing patients with CLL has evolved over the first 6 months of the COVID-19 pandemic, from Clinical Care Options (CCO)

person default Jacob D. Soumerai, MD Released: September 30, 2020

Commentary from David Marks, MD, PhD, on considerations for using blinatumomab vs inotuzumab ozogamicin in the treatment of relapsed/refractory ALL, from CCO

Released: September 30, 2020

Expert commentary from Danielle M. Brander, MD, on the implications of MRD evaluation in patients with CLL, as reported by Clinical Care Options (CCO)

Danielle Brander, MD Released: September 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue